UP!

HUM $325.3

HUM target price
325.30
265
652
Humana Inc.
Type
Public
Traded as NYSE: HUM
S&P 500 Component
Industry Managed health care
Founded August 18, 1961; 56 years ago (1961-08-18) (as Extendicare Inc.)
Louisville, Kentucky, U.S.
Headquarters Humana Building
Louisville, Kentucky, U.S.
Key people
  • Kurt J. Hilzinger (Chairman)
  • Bruce D. Broussard (CEO and President)
Revenue Increase US$ 54.379 billion (2016)
Net income
Decrease US$ 0.614 billion (2016)
Total assets Increase US$ 25,396 billion (2016)
Total equity Increase US$ 10.625 billion (2016)
Number of employees
51,600 (2016)
Website www.humana.com

Humana Inc. is a for-profit American health insurance company based in Louisville, Kentucky. As of 2014 Humana has had over 13 million customers in the U.S., reported a 2013 revenue of US$41.3 billion, and has had 51,600 employees. In 2013, the company ranked 73 on the Fortune 500 list, which made it the highest ranked (by revenues) company based in Kentucky. It has been the third largest health insurance in the nation.

The U.S. Dept. of Health and Human Services investigated Humana in 2009 for sending flyers to Medicare recipients that the AARP characterized as deceptive. The company's managed care model has also been criticized for ethical lapses and limitations.

The health insurer Aetna said on July 3, 2015, that it had agreed to acquire its smaller rival Humana for $37 billion in cash and stock but walked away from the deal after a court ruling that the merger would be anti-competitive.

Lawyers David A. Jones, Sr. and Wendell Cherry founded a nursing home company in 1961. The company known in 1968 as Extendicare Inc., became the largest nursing home company in the United States. In 1972, Jones and Cherry sold the nursing home chain, to purchase hospitals.

In 1974, the partners changed the corporate name to Humana Inc. The name was meant to change public perception from 'warehousing' or indifferently treating people to providing a higher-level of human care and, by extension, more humane care. It grew in the following years, both by business and in 1978 through the takeover of American Medicorp Inc., which doubled the company's size, and growing into the world's largest hospital company in the 1980s. During this period, Humana developed the double corridor model for hospital construction. This design minimized the distance between patients and nurses by placing nursing support services in the interior of the building with patient rooms surrounding the perimeter .

As the American health care system changed in the 1980s, "one of its hospitals in Arizona lost a contract with the largest health-maintenance organization in the area [and] Humana created its own health insurance plan.

In 1993, Humana had become the largest hospital operator in the country owning 77 hospitals. Humana executives spun off hospital operations from health insurance operations, to create Galen Health Care. The following year they sold the 73 hospitals of Galen Health Care Inc. to Nashville-based Columbia Hospital Corporation of America for $3.4 billion.

In 1998, one year after Jones has stepped aside as CEO, United Healthcare made an unsuccessful attempt to acquire Humana. Humana pulled out of the acquisition after United stock dropped $2.9 billion in value. In 2001, Humana was a cofounder of Availity.

In 2005, Humana entered into a business partnership with Virgin Group, offering financial incentives to members for healthy behavior, such as regular exercise.

On November 16, 2006, The Centers for Disease Control and Prevention (CDC) and Humana Inc. partnered to expand on traditional private-sector approaches to population health management.

In 2006, Humana launched an education campaign to market Medicare Advantage (MA) and Prescription Drug Plans (PDP) nationwide to Medicare eligible consumers, following the passage of the Medicare modernization act. The same year Humana launched RightSource, a national mail-order retail pharmacy business. In its March 2008 issue, Fortune Magazine named Humana one of the Top 5 Most Admired Healthcare Companies in the United States.

In 2010, Humana bought Texas-based Concentra Inc., which owns urgent-care and physical therapy centers, for $790 million, effectively returning to health care services. In May 2011, Humana announced it would be using mobileStorm to transmit protected health information to patients.

In March 2015, Humana announced the sale of Concentra to private equity firm Welsh, Carson, Anderson & Stowe and Select Medical Holdings Corporation for about $1 billion, with proceeds to fund a "$2 billion share buyback program and other corporate spending".

On July 3, 2015, Aetna announced that it would acquire Humana for $37 billion in cash and stock (approximately $230 a share at that time). Aetna and Humana shareholders would own 74% and 26% of the new combined company. The merger was blocked by a federal judge in January 2017. The companies can appeal the ruling. On February 14, 2017, Aetna Inc. and Humana Inc. quashed a $34 billion merger agreement, after judges ruled against the merger for a second time.

The Humana Building in Louisville, Kentucky is an example of postmodern architecture designed by Michael Graves and completed in 1985.

Humana's mail-order facility, Humana Pharmacy has operated out of Phoenix, Arizona and West Chester, Ohio. Humana's call centers are located in Cincinnati, Ohio and other areas.

LPGA player Nancy Scranton is a spokesperson for Humana. In the past, PGA Tour player David Toms' David Toms Foundation has partnered with the Humana Foundation to provide grants to several children's charities in New Orleans. Humana is the official health benefits provider of the PGA Tour and Champions Tour.

The Humana Distaff Handicap is a Grade 1 race for thoroughbred fillies and mares, four-years-old and up. The race is run each spring on Kentucky Derby day at Churchill Downs and set at a distance of 7 furlongs for a purse of $250,000.

Humana is the presenting sponsor of the Grand Ole Opry.

Since 1979 Humana has been a principal sponsor of the annual Humana Festival of New American Plays in Louisville, Kentucky.

In 1993 Humana founded Humana Military Healthcare Services (HMHS) as a wholly owned subsidiary.

From 2004 to 2009, HMHS was the managed care contractor for the Department of Defense Military Health System TRICARE South Region. In 2009, HMHS' Managed Care Support Contract was awarded to United Military and Veterans Services, a subsidiary of UnitedHealth Group. HMHS protested that decision and the Government Accountability Office upheld the protest in late 2009. In 2011, HMHS regained the five-year contract to administer medical benefits to military members and families in the South region, a contract worth $23.5 billion.

In 1987, Humana sued NBC over a story line in the television medical drama St. Elsewhere whereas the hospital was to be sold to a for-profit medical corporation and renamed "Ecumena," with subsequent changes to the hospital, both positive and negative, emanating from that change. Humana was successful at forcing NBC into showing a disclaimer at the beginning of the September 30 episode saying that the drama had no connection whatsoever with Humana.

On May 30, 1996, Linda Peeno, a physician who was contracted to work for Humana for nine months, testified before Congress as to the downside of managed care. Peeno said she was effectively rewarded by her employer for causing the death of a patient, because it saved the company a half-million dollars. Peeno stated that she felt the "managed care" model was inherently unethical.

In 1999 season one of Michael Moore's TV series The Awful Truth featured Humana refusing to pay for a diabetic patient with pancreatic failure needing a transplant. A contradictory policy stated that all of this man's diabetes related expenses were covered by his plan, but another section stated that it did not cover organ transplants. Moore conducted a fake funeral on the front steps of the Humana building and three days later, Humana changed their policy and authorized the man's treatment..

Michael Moore's 2007 documentary Sicko used the video of Linda Peeno's testimony. On June 28, 2007, Humana declared that Peeno was never a Humana "associate" (permanent, full-time employee), but rather a "part-time contractor". Humana disputed portions of her Congressional testimony by saying that because the patient's healthcare plan did not cover heart transplants, denial of coverage was valid.

On September 21, 2009 the U.S. Department of Health and Human Services opened an investigation into Humana mass mailings to elderly Medicare recipients. The mail was made to appear to contain official information about Medicare Advantage and prescription drug benefit information, but instead alleged that core Medicare benefits could be cut by the Obama administration's healthcare reform, a claim refuted by John Rother, AARP's executive vice president. Douglas Elmendorf, the head of the Congressional Budget Office (CBO) supported the claim that Medicare benefits could be cut, but his comments were in reference to just one of several congressional bills. CBO estimates of another healthcare reform bill found that changes to premiums would vary. The Centers for Medicare and Medicaid Services instructed Humana to cease all such mailings to Medicare plan members pending an investigation. HHS Secretary Kathleen Sebelius, in a letter to the insurance industry, threatened that bad actors may be excluded from new health insurance markets that were to open in 2014. Senate Republicans pointed out in a letter to Sebelius, that a 1997 directive from the Centers for Medicare and Medicaid Services explicitly allowed HMOs to tell members about legislation and urge them to express opinions.

As of June 19, 2017 the Humana Military android app is rated at 2.3 out of 5 stars, based on 91 reviews. [1] The Humana Military apple app is rated at 1.5 stars out of 5, based on 28 ratings.[2]

As of August 4, 2017 the MyHumana android app is rated 4 out of 5 stars, based on 877 reviews. [3] The MyHumana apple app is rated 3 stars out of 5, based on 377 ratings. [4]

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2022 2023-02-01 1.62 1.62
Q3 2022 2022-11-02 6.88 6.88
Q2 2022 2022-07-27 8.67 8.67
Q1 2022 2022-04-27 8.04 8.04
Q4 2021 2022-02-02 1.24 1.24
Q3 2021 2021-11-03 4.83 4.83
Q2 2021 2021-07-28 6.89 6.89
Q1 2021 2021-04-28 7.67 7.67
Q4 2020 2021-02-03 -2.30 -2.30
Q3 2020 2020-11-03 3.08 3.08

Ratings

2016-07-09 Reiterated Rating Cantor Fitzgerald Buy
2016-07-08 Downgrade JPMorgan Chase & Co. Overweight to Neutral $196.00 to $150.00
2016-06-28 Initiated Coverage Wolfe Research Market Perform $244.00
2016-06-28 Reiterated Rating Credit Suisse Hold
2016-06-28 Reiterated Rating Credit Suisse Group AG Hold
2016-06-21 Reiterated Rating Leerink Swann Outperform
2016-05-22 Reiterated Rating Morgan Stanley Hold
2016-05-19 Reiterated Rating Leerink Swann Buy $230.00
2016-05-05 Reiterated Rating Credit Suisse Hold
2016-05-05 Boost Price Target RBC Capital Sector Perform $209.00 to $220.00
2016-05-05 Boost Price Target Stifel Nicolaus Buy $209.00 to $220.00
2016-05-05 Boost Price Target Royal Bank Of Canada Sector Perform $209.00 to $220.00
2016-04-05 Reiterated Rating Leerink Swann Outperform
2016-04-05 Reiterated Rating Cowen and Company Outperform
2016-02-16 Lower Price Target JPMorgan Chase & Co. Overweight $201.00 to $196.00
2016-02-14 Reiterated Rating FBR & Co. Market Perform $208.00
2016-02-14 Reiterated Rating FBR & Co Market Perform $208.00
2016-02-11 Reiterated Rating Cantor Fitzgerald Buy $230.00
2016-02-05 Reiterated Rating Leerink Swann Outperform $230.00
2016-01-15 Lower Price Target Susquehanna $197.00 to $180.00
2015-12-16 Initiated Coverage Credit Suisse Neutral $185.00
2015-11-09 Reiterated Rating Leerink Swann Buy $230.00
2015-11-09 Lower Price Target RBC Capital Sector Perform $223.00 to $215.00
2015-09-18 Upgrade Cantor Fitzgerald Buy
2015-09-16 Initiated Coverage JPMorgan Chase & Co. Overweight $210.00
2015-09-08 Lower Price Target RBC Capital Sector Perform $230.00 to $223.00
2015-07-30 Reiterated Rating Barclays Equal Weight $180.00 to $193.00
2015-07-30 Reiterated Rating Barclays PLC Equal Weight $180.00 to $193.00
2015-07-12 Reiterated Rating Cantor Fitzgerald Buy
2015-07-09 Lower Price Target Susquehanna Neutral $215.00 to $213.00
2015-07-08 Reiterated Rating FBR & Co. Hold
2015-07-07 Boost Price Target Leerink Swann $230.00
2015-07-07 Downgrade Argus Buy to Hold
2015-07-07 Boost Price Target FBR & Co. Market Perform $150.00 to $230.00
2015-07-06 Reiterated Rating Cantor Fitzgerald Buy $230.00
2015-07-06 Downgrade Wedbush Outperform to Neutral $230.00
2015-07-02 Reiterated Rating Argus Buy to Buy $180.00 to $220.00
2015-06-24 Initiated Coverage RBC Capital Sector Perform $221.00
2015-06-23 Set Price Target Deutsche Bank Hold $220.00 to $195.00
2015-06-23 Set Price Target Deutsche Bank AG Hold $220.00 to $195.00
2015-06-03 Upgrade Sterne Agee CRT Underperform to Neutral
2015-06-01 Reiterated Rating Morgan Stanley Hold
2015-06-01 Reiterated Rating Wedbush Outperform
2015-06-01 Set Price Target Leerink Swann Buy $200.00 to $220.00
2015-06-01 Boost Price Target Deutsche Bank Hold $155.00 to $220.00
2015-06-01 Reiterated Rating Cantor Fitzgerald Buy $160.00 to $230.00
2015-05-13 Downgrade Sterne Agee CRT Neutral to Underperform $165.00 to $150.00
2015-05-12 Reiterated Rating Oppenheimer Outperform $188.00
2015-05-12 Reiterated Rating Oppenheimer Holdings Inc. Outperform $188.00
2015-05-07 Boost Price Target Leerink Swann Outperform $195.00 to $200.00
2015-04-30 Lower Price Target Barclays Equal Weight $190.00 to $180.00
2015-04-30 Lower Price Target Deutsche Bank Hold $170.00 to $160.00
2015-04-30 Lower Price Target Jefferies Group Hold $189.00 to $179.00
2015-04-30 Lower Price Target Oppenheimer Outperform $193.00 to $188.00
2015-04-30 Boost Price Target FBR & Co. Outperform $145.00 to $150.00
2015-03-24 Boost Price Target Oppenheimer Outperform $167.00 to $193.00
2015-03-20 Boost Price Target Barclays Equal Weight $155.00 to $190.00
2015-02-23 Boost Price Target Argus Buy $155.00 to $180.00
2015-02-05 Boost Price Target FBR & Co. Hold $132.00 to $145.00
2015-01-08 Boost Price Target Barclays Equal Weight $141.00 to $155.00
2015-01-06 Boost Price Target Argus Buy $135.00 to $155.00
2015-01-06 Upgrade Deutsche Bank Sell to Hold $115.00 to $140.00
2015-01-05 Downgrade Raymond James Outperform to Market Perform $151.00
2015-01-05 Downgrade Raymond James Financial Inc. Outperform to Market Perform $151.00
2014-12-05 Boost Price Target JPMorgan Chase & Co. Overweight $150.00 to $155.00
2014-12-05 Reiterated Rating Cantor Fitzgerald Buy $145.00 to $160.00
2014-12-05 Boost Price Target Bank of America Neutral $146.00 to $150.00
2014-12-05 Boost Price Target Bank of America Corp. Neutral $146.00 to $150.00
2014-11-18 Reiterated Rating Bank of America Hold $140.00 to $146.00
2014-11-10 Reiterated Rating Credit Suisse Neutral $123.00 to $140.00
2014-11-07 Upgrade Goldman Sachs Sell to Neutral
2014-11-07 Upgrade Goldman Sachs Group Inc. Sell to Neutral
2014-09-22 Reiterated Rating Citigroup Inc. Sell $95.00 to $97.00
2014-09-22 Boost Price Target Jefferies Group Hold $117.00 to $126.00
2014-09-19 Reiterated Rating JPMorgan Chase & Co. Overweight $150.00 to $155.00
2014-09-17 Boost Price Target Goldman Sachs $117.00 to $130.00
2014-08-07 Reiterated Rating Raymond James Outperform $123.00 to $128.00
2014-08-01 Boost Price Target Leerink Swann $140.00
2014-07-31 Boost Price Target Barclays Equal Weight $120.00 to $128.00
2014-07-31 Reiterated Rating Credit Suisse Neutral $121.00 to $123.00
2014-07-16 Reiterated Rating Deutsche Bank Sell $100.00 to $110.00
2014-07-11 Boost Price Target Leerink Swann Outperform $140.00 to $150.00
2014-06-27 Initiated Coverage Sterne Agee CRT Neutral $139.00
2014-06-06 Upgrade Stifel Hold to Buy $155
2014-06-06 Upgrade Stifel Nicolaus Hold to Buy $155.00
2014-05-23 Reiterated Rating Leerink Swann Outperform $135.00 to $140.00
2014-05-22 Boost Price Target Argus Buy $125.00 to $135.00
2014-05-12 Boost Price Target Deutsche Bank Sell $95.00 to $100.00
2014-05-09 Boost Price Target BMO Capital Markets $104.00 to $120.00
2014-05-09 Reiterated Rating Raymond James Outperform $117.00 to $123.00
2014-05-09 Boost Price Target Wedbush $125.00 to $134.00
2014-05-09 Boost Price Target Cantor Fitzgerald $130.00 to $135.00
2014-05-08 Boost Price Target Oppenheimer Outperform $105.00 to $125.00
2014-05-08 Reiterated Rating Credit Suisse Neutral $98.00 to $121.00
2014-05-08 Boost Price Target Barclays Equal Weight $105.00 to $120.00
2014-05-08 Boost Price Target Leerink Swann Outperform $120.00 to $130.00
2014-05-08 Reiterated Rating Bank of America Neutral $124.00 to $126.00
2014-05-07 Boost Price Target FBR & Co. Market Perform $99.00 to $110.00
2014-04-10 Boost Price Target Susquehanna Neutral $101.00 to $110.00
2014-04-08 Boost Price Target Cowen and Company $110.00 to $120.00
2014-04-03 Boost Price Target Deutsche Bank Sell $87.00 to $95.00
2014-03-27 Boost Price Target Cantor Fitzgerald $105.00 to $130.00
2014-03-20 Boost Price Target JPMorgan Chase & Co. $120.00 to $150.00
2014-03-07 Downgrade Jefferies Group Buy to Hold $111.00
2014-02-26 Downgrade Citigroup Inc. Neutral to Sell $95.00
2014-02-06 Lower Price Target Jefferies Group $115.00 to $111.00
2014-01-08 Downgrade Barclays Overweight to Equal Weight $109.00
2014-01-07 Downgrade Deutsche Bank Hold to Sell $100.76 to $87.00
2013-11-21 Initiated Coverage Morgan Stanley Equal Weight
2013-11-20 Boost Price Target JPMorgan Chase & Co. Overweight $110.00 to $120.00
2013-11-19 Initiated Coverage Leerink Swann Outperform to Outperform $120.00
2013-11-15 Boost Price Target Argus Buy $102.00 to $110.00
2013-11-13 Initiated Coverage FBR & Co. Market Perform $92.00
2013-11-07 Boost Price Target Jefferies Group Buy $105.00 to $115.00
2013-11-07 Boost Price Target Credit Suisse Neutral $93.00 to $98.00
2013-11-07 Lower Price Target Deutsche Bank Hold $94.00 to $87.00
2013-11-05 Downgrade Monness Crespi & Hardt Buy to Neutral
2013-10-08 Boost Price Target Deutsche Bank Hold $86.00 to $91.00
2013-08-14 Reiterated Cantor Fitzgerald Buy $90 to $105
2013-07-31 Reiterated Monness Crespi & Hardt Buy $108 to $114
2013-07-03 Reiterated Argus Buy $82 to $92
2016-07-09 Reiterated Rating Cantor Fitzgerald Buy
2016-07-08 Downgrade JPMorgan Chase & Co. Overweight to Neutral $196.00 to $150.00
2016-06-28 Initiated Coverage Wolfe Research Market Perform $244.00
2016-06-28 Reiterated Rating Credit Suisse Hold
2016-06-28 Reiterated Rating Credit Suisse Group AG Hold

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
MCCALLISTER MICHAEL B 0.07%  (111859) FITB / HUM / T / ZTS /
LISTON THOMAS J President - Retail Segment 0.07%  (105443) HUM /
BROUSSARD BRUCE D President 0.06%  (88652) HUM / KEY / USPH /
MURRAY JAMES E EVP & COO 0.02%  (34668) HUM /
BLOEM JAMES H Sr. VP, CFO & Treasurer 0.02%  (30326) HUM / SKH /
DAMELIO FRANK A 0.01%  (20108) HUM / PFE / ZTS /
Bierbower Elizabeth D Segment Pres., Employer Group 0.01%  (19879) HUM /
HILZINGER KURT J 0.01%  (19448) HUM / ONS /
Kusserow Paul B. K. Sr VP & Ch Strat Dev Officer 0.01%  (19347) AMED / CNXR / HUM /
Kane Brian A SVP & Chief Financial Officer 0.01%  (18459) HUM /
PERKINS BRUCE D Sgmnt Pres, Health&Well-Being 0.01%  (15946) AMED / HUM /
McCulley Steven E Vice President & Controller 0.01%  (14916) HUM /
BEVERIDGE, ROY A Sr. VP & Chief Medical Officer 0.01%  (14087) HUM /
HUNTER CHRISTOPHER H. SVP and Chief Strategy Officer 0.01%  (12388) HUM /
BILNEY JODY L SVP & Chief Consumer Officer 0.01%  (10860) BLMN / DOOR / HUM /
Christopher M Todoroff Sr. VP and General Counsel 0.01%  (9423) HUM /
Huval Timothy S. Senior VP & Chief HR Officer 0.01%  (8831) HUM / SBCF /
LeClaire Brian P. SVP & Chief Service & Info Off 0.01%  (8703) HUM /
Fleming William Kevin President, Hlthcare Svc Sgmt 0.01%  (8143) HUM /
MARGULIS HEIDI S Senior V.P. - Public Affairs 0.01%  (7776) HUM /
Zipperle Cynthia H Vice President, CAO,Controller 0.01%  (7771) HUM /